This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Poxel. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Guntram Koller: Innovator in Enantiomer Separation Technology
Introduction
Guntram Koller is a notable inventor based in Germany, recognized for his contributions to the field of chemistry, particularly in the separation of enantiomers. His innovative approach to isolating enantiomer components has the potential to impact various applications in pharmaceuticals and materials science.
Latest Patents
Guntram Koller holds a patent titled "Process Of Isolating Enantiomer Components From Enantiomer Mixtures By Particle-Size-Controlled Crystallization." This invention outlines a method for isolating enantiomer components from a mixture through a series of controlled crystallization steps. The process involves forming a solution of enantiomers, seeding with differently sized crystals, inducing simultaneous crystallization, and isolating the enriched crystals through size separation techniques.
Career Highlights
Guntram Koller is currently associated with Poxel, a company focused on developing innovative treatments for metabolic diseases. His work at Poxel emphasizes the importance of precise chemical processes in drug development and formulation.
Collaborations
Guntram collaborates with talented professionals in his field, including David Maillard and Ewgenij Wakaresko. These collaborations enhance the research and development efforts at Poxel, fostering an environment of innovation and scientific advancement.
Conclusion
Guntram Koller is a significant figure in the realm of enantiomer separation technology, with a focus on innovative processes that can lead to advancements in various scientific fields. His contributions continue to shape the landscape of chemical engineering and pharmaceutical development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile